PPARG and neoplasm: Recently, we have shown that sporadic colorectal cancers (CRCs) presenting reduced PPARγ expression levels are significantly associated with patients' worse prognosis; in the same type of tumours, PPARG has been shown to be an independent prognostic factor [9], [10], suggesting the possibility to target this gene with drugs in clinical applications [10].